Application 210391
- Type
- ANDA
- Sponsor
- CIPLA LIMITED
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 002 | ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE | ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE | TABLET | 50MG | No | No |
| 003 | ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE | ABACAVIR, DOLUTEGRAVIR, LAMIVUDINE | TABLET | 300MG | No | No |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.